Showing results (21-30 of 95) with videos related to

Sort By:
Pageof 10
Blood|March 8, 2024
In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasmsAngelo B A Laranjeira, Tim Kong, Steven C Snyder, et al.
British Journal of Haematology|February 22, 2017
A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosisSrdan Verstovsek, Michael R Savona, Ruben A Mesa, et al.
Experimental Hematology|April 3, 2022
Toll-like receptor and cytokine expression throughout the bone marrow differs between patients with low- and high-risk myelodysplastic syndromesLuana Chiquetto Paracatu, Darlene A Monlish, Zev J Greenberg, et al.
Biorxiv : the Preprint Server for Biology|October 3, 2025
JAK2 V617F Myeloproliferative Neoplasms Support Parallel Evolution of Independent Leukemic ClonesTyler M Parsons, Aishwarya Krishnan, Infencia Xavier Raj, et al.
Cancer|May 2, 2022
Defining disease modification in myelofibrosis in the era of targeted therapyNaveen Pemmaraju, Srdan Verstovsek, Ruben Mesa, et al.
Research Square|December 3, 2025
Parallel Evolution of Leukemic Clones in Myeloproliferative NeoplasmsTyler M Parsons, Aishwarya Krishnan, Infencia Xavier Raj, et al.
Expert Review of Hematology|June 19, 2026
Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparisonNaveen Pemmaraju, Alessandro Lucchesi, Stephen T Oh, et al.
Leukemia|February 6, 2019
Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signalingDaniel A C Fisher, Cathrine A Miner, Elizabeth K Engle, et al.
Experimental Hematology|February 10, 2024
Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasmsTaylor B Collins, Angelo B A Laranjeira, Tim Kong, et al.
Pageof 10